| Health / Medical Topics |
NA17-A Antigen
A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues. (NCI Thesaurus)
YOU MAY ALSO LIKE
A synthetic peptide vaccine derived from the melanoma antigen NA17. Dendritic cells (DC) harvested from a cancer patient may be exposed to…
Sodium ion requiring one electron to return to its elemental state.
A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3…
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding…
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3c TNM…
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3b TNM…
